Today: 9 April 2026
Subscribe
Browse Category

Pfizer News 5 December 2025 - 13 March 2026

Pfizer Stock Price Today: Shares Slip After GSK RSV Move Offsets Eliquis Data

Pfizer Stock Price Today: Shares Slip After GSK RSV Move Offsets Eliquis Data

Pfizer shares closed down 1% at $26.60 Friday after GSK’s RSV vaccine won expanded FDA approval for at-risk adults 18 to 49, narrowing Pfizer’s lead in the RSV market. Positive trial data for Pfizer’s blood thinner Eliquis offset some pressure, but the stock finished near session lows amid broader market weakness and uncertainty over the company’s near-term growth outlook.
13 March 2026
···
Pfizer stock today: PFE edges down as Wall Street looks to Feb. 3 results update

Pfizer stock today: PFE edges down as Wall Street looks to Feb. 3 results update

Pfizer shares slipped 0.1% to $25.06 in thin holiday trading Monday, with the stock moving between $24.99 and $25.19. Investors focused on Pfizer’s 2026 outlook and pipeline moves, including a $150 million licensing deal with China’s YaoPharma for an experimental obesity drug. Broader U.S. markets declined as tech stocks retreated. Pfizer expects revenue growth to resume in 2029.
29 December 2025
···
Pfizer Stock (PFE) Update: Shares Hold Near $25 Into Year-End as Investors Weigh 2026 Guidance, Dividend, and Pipeline Catalysts

Pfizer Stock (PFE) Update: Shares Hold Near $25 Into Year-End as Investors Weigh 2026 Guidance, Dividend, and Pipeline Catalysts

Pfizer shares closed Friday at $25.09, trading in a narrow range on light volume ahead of the New Year’s holiday. No new company press releases have appeared since Dec. 18. The stock remains below its 52-week high of $27.69, with dividend yield drawing investor focus as Wall Street weighs declining COVID revenues against future growth in oncology and obesity drugs.
27 December 2025
···
Pfizer (PFE) Stock News, Forecasts and Analyst Outlook as of Dec. 25, 2025

Pfizer (PFE) Stock News, Forecasts and Analyst Outlook as of Dec. 25, 2025

Pfizer shares closed at $25.03 on Dec. 24, ahead of Christmas, after the company issued 2026 guidance below Wall Street forecasts. The drugmaker projected 2026 revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, citing lower COVID product sales and loss of exclusivity. Pfizer declared a $0.43 per share Q1 2026 dividend, its 349th consecutive payout.
25 December 2025
···
Pfizer Stock (PFE) Forecast and News: 2026 Guidance, Drug-Pricing Deals, and Pipeline Catalysts to Watch on Dec. 19, 2025

Pfizer Stock (PFE) Forecast and News: 2026 Guidance, Drug-Pricing Deals, and Pipeline Catalysts to Watch on Dec. 19, 2025

Pfizer shares traded near $25.04 midday Friday after a volatile week, holding steady despite new policy headlines and a guidance reset. The company issued 2026 revenue guidance of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, both below Wall Street estimates. Pfizer also reported positive Phase 3 results for PADCEV + Keytruda in bladder cancer.
19 December 2025
···
Pfizer Stock (PFE) on Dec. 18, 2025: Latest News, 2026 Forecast, Analyst Price Targets, Dividend, and Key Catalysts

Pfizer Stock (PFE) on Dec. 18, 2025: Latest News, 2026 Forecast, Analyst Price Targets, Dividend, and Key Catalysts

Pfizer shares traded at $25.04 on Dec. 18, 2025, down 1.8% after management issued cautious 2026 guidance with revenue forecast at $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00. The company cited lower COVID product sales and patent expirations as major headwinds. Pfizer stock has dropped over 50% since early 2023. Investors remain focused on its dividend yield and oncology developments.
18 December 2025
··
Pfizer Stock (PFE) After Hours Today (Dec. 17, 2025): What to Know Before the Market Opens Thursday

Pfizer Stock (PFE) After Hours Today (Dec. 17, 2025): What to Know Before the Market Opens Thursday

Pfizer shares closed down 1.9% at $25.04 Wednesday, hitting session lows despite positive Phase 3 results for PADCEV plus KEYTRUDA in bladder cancer. The stock edged up to $25.07 after hours. Investors weighed new 2026 guidance projecting $59.5–$62.5 billion in revenue and a $1.5 billion decline in COVID-19 product sales. Broader U.S. market weakness also pressured the stock.
18 December 2025
··
Pfizer Stock (PFE) Today: 2026 Guidance Triggers Fresh Scrutiny—News, Forecasts, Analyst Targets and Dividend Outlook (Dec. 17, 2025)

Pfizer Stock (PFE) Today: 2026 Guidance Triggers Fresh Scrutiny—News, Forecasts, Analyst Targets and Dividend Outlook (Dec. 17, 2025)

Pfizer shares traded near $25.50 Wednesday after the company issued 2026 revenue guidance of $59.5–$62.5 billion and forecast adjusted EPS of $2.80–$3.00, below Wall Street expectations. The company also cut its 2025 revenue outlook to about $62 billion. Shares fell about 5% after the update. Pfizer cited lower COVID product sales and ongoing patent losses as key headwinds.
17 December 2025
···
Pfizer Stock (NYSE: PFE) News Today: 2026 Guidance, Earnings Forecasts, Analyst Price Targets and Key Catalysts

Pfizer Stock (NYSE: PFE) News Today: 2026 Guidance, Earnings Forecasts, Analyst Price Targets and Key Catalysts

Pfizer shares fell 3.4% to $25.53 late Dec. 16 after the company issued 2026 guidance projecting flat-to-declining revenue and adjusted EPS of $2.80–$3.00. The outlook cited lower COVID product sales and a $1.5 billion hit from patent expirations. Pfizer expects no share buybacks through 2026. Wall Street noted the EPS target is slightly below consensus.
17 December 2025
····
Pfizer Stock (PFE) Before Market Open Dec. 15, 2025: Key News, 2026 Guidance Call, Analyst Targets, Dividend, and Risks

Pfizer Stock (PFE) Before Market Open Dec. 15, 2025: Key News, 2026 Guidance Call, Analyst Targets, Dividend, and Risks

Pfizer closed Friday at $25.85, near the upper end of its 52-week range. Investors are focused on the company’s analyst call Tuesday, where management will issue 2026 financial guidance. Pfizer’s dividend yield remains in the mid-6% range, while short interest stands at about 2.45% of float. Policy uncertainty for COVID vaccines and efforts to grow oncology and cardiometabolic revenue remain in focus.
14 December 2025
··
Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA “Black Box” Headline, Analyst Forecasts — What to Know Before the Next Market Open

Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA “Black Box” Headline, Analyst Forecasts — What to Know Before the Next Market Open

Pfizer shares closed at $25.85 on Dec. 12, 2025, up 0.19%, and edged to $25.89 in after-hours trading. The company declared a $0.43 per-share dividend for Q1 2026. Trading volume reached 50.8 million shares during the session, with 1.56 million shares after hours. U.S. markets remain closed until Monday, Dec. 15.
13 December 2025
··
Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA Vaccine Warning Headlines, and What to Watch Before the Next Market Open

Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA Vaccine Warning Headlines, and What to Watch Before the Next Market Open

Pfizer shares closed up 0.19% at $25.85 Friday, with after-hours trading lifting the stock slightly to $25.88. The company declared a $0.43 per-share quarterly dividend, payable March 6, 2026. Investors also reacted to reports of a possible FDA “black box” warning for COVID-19 vaccines and new late-stage data on breast-cancer drug Tukysa.
13 December 2025
··
Pfizer (PFE) Stock Today: Price, Metsera Obesity Deal, 2025–2026 Forecast and Key Risks

Pfizer (PFE) Stock Today: Price, Metsera Obesity Deal, 2025–2026 Forecast and Key Risks

Pfizer shares traded near $26 late December 5, up about 1%, with a market cap of $146 billion and a dividend yield close to 7%. New analyst coverage flagged tighter FDA COVID vaccine rules and looming patent expirations for key drugs as risks. The stock remains 36% below its five-year level despite recent gains. Investors await updated 2026 guidance and details on a major obesity-drug acquisition.
5 December 2025
···
1 2

Stock Market Today

  • LANXESS Sees 31% Share Price Surge in One Month After Decline
    April 8, 2026, 10:14 PM EDT. LANXESS (XTRA:LXS) reversed a 21% one-year loss with a sharp 31% share price rebound over the past month. The stock trades near €17.63, close to an average analyst price target of €17.81, signaling potential undervaluation amid ongoing portfolio optimization and digitalization efforts. Investors anticipate improved operating leverage, higher free cash flow, and better returns on capital despite risks from European energy costs and competition. This rapid sentiment shift highlights debate over intrinsic value versus market expectations. Analysts suggest closely monitoring the stock's fundamentals and broader market trends to assess growth potential against prevailing headwinds.

Latest article

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

8 April 2026
IREN shares rose 1.8% to $35.74 Wednesday as investors assessed its $6 billion share program and shift from bitcoin mining to AI cloud services. The company’s revenue fell to $184.7 million last quarter, with a net loss of $155.4 million. IREN recently announced a five-year, $9.7 billion AI cloud deal with Microsoft. Options trading volume hit 103,000 contracts Tuesday, with sentiment described as mixed.
Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

8 April 2026
Amazon closed at $213.77 Tuesday, with BNP Paribas maintaining a $320 price target, citing strong AI demand despite Amazon’s planned $200 billion capex for 2026. The company’s February forecast of higher spending sent shares down 11.5% after hours, even as AWS revenue rose 24% to $35.6 billion in the December quarter. Alphabet and Microsoft are also ramping up AI infrastructure spending.
Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

8 April 2026
The Sensex surged 2,946 points to 77,562.90 on Wednesday, its best day in five years, as a U.S.-Iran ceasefire and steady RBI rates pushed Indian markets higher. Brent crude fell 14.4% to $93.49 a barrel, easing pressure on the rupee, which rose 0.5% to 92.58 per dollar. All 16 major sectors gained, led by financials and auto stocks. The RBI kept its repo rate at 5.25% and forecast slower growth ahead.
Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

8 April 2026
Stock Yards Bank & Trust Co. increased its Netflix stake by 1,141.9% to 29,074 shares in Q4, while Ethos Capital Management disclosed a new 19,610-share position worth $1.84 million. The moves come ahead of Netflix’s April 16 earnings report and follow a Goldman Sachs upgrade to Buy with a $120 target. Insiders Reed Hastings and Greg Peters sold shares earlier this year under preset trading plans. Netflix last traded at $98.82.
Alphabet Stock (GOOG, GOOGL) Faces Split Fund Bets Ahead of Earnings After Fresh 13F Reports

Alphabet Stock (GOOG, GOOGL) Faces Split Fund Bets Ahead of Earnings After Fresh 13F Reports

8 April 2026
Zevenbergen Capital increased its Alphabet Class A share holdings by 27.4% in Q4, while Lombard Odier and Empirical Wealth Management reduced their Class C positions, according to April 7 filings. Alphabet will report first-quarter results on April 29. GOOG and GOOGL traded near $304 before Wednesday’s U.S. open. The filings reflect holdings as of December 31 and may not show current positions.
Go toTop